Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX)‘s stock had its “sell” rating reiterated by analysts at Mizuho in a research report issued on Tuesday. They presently have a $7.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $8.00. Mizuho’s price target would suggest a potential downside of 47.13% from the stock’s current price.

A number of other research firms have also weighed in on VRX. Wells Fargo & Co reaffirmed an “underperform” rating on shares of Valeant Pharmaceuticals International in a research report on Monday, June 12th. J P Morgan Chase & Co reaffirmed a “hold” rating on shares of Valeant Pharmaceuticals International in a research report on Tuesday, May 9th. Zacks Investment Research lowered Valeant Pharmaceuticals International from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 13th. Stifel Nicolaus reaffirmed a “buy” rating and set a $35.00 price objective on shares of Valeant Pharmaceuticals International in a research report on Thursday, August 10th. Finally, BidaskClub raised Valeant Pharmaceuticals International from a “sell” rating to a “hold” rating in a research report on Friday, June 23rd. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have assigned a buy rating to the stock. Valeant Pharmaceuticals International presently has a consensus rating of “Hold” and an average price target of $17.67.

Valeant Pharmaceuticals International (NYSE VRX) traded up 0.038% during mid-day trading on Tuesday, reaching $13.245. The company had a trading volume of 12,629,133 shares. Valeant Pharmaceuticals International has a one year low of $8.31 and a one year high of $31.84. The firm’s 50-day moving average is $15.84 and its 200-day moving average is $13.40. The firm’s market capitalization is $4.62 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.05 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.97 by $0.08. Valeant Pharmaceuticals International had a positive return on equity of 59.89% and a negative net margin of 12.40%. The company had revenue of $2.23 billion during the quarter, compared to analyst estimates of $2.23 billion. During the same quarter last year, the company earned ($0.88) EPS. The firm’s revenue for the quarter was down 7.7% on a year-over-year basis. On average, equities research analysts anticipate that Valeant Pharmaceuticals International will post $3.89 earnings per share for the current fiscal year.

WARNING: This story was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://www.watchlistnews.com/valeant-pharmaceuticals-international-inc-vrx-rating-reiterated-by-mizuho/1529705.html.

In related news, Director Schutter Richard U. De bought 10,000 shares of the stock in a transaction that occurred on Monday, August 21st. The shares were bought at an average cost of $14.33 per share, for a total transaction of $143,300.00. Following the completion of the transaction, the director now owns 77,479 shares of the company’s stock, valued at $1,110,274.07. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.87% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in VRX. Cetera Investment Advisers bought a new position in Valeant Pharmaceuticals International during the second quarter valued at $192,000. Scotia Capital Inc. increased its position in Valeant Pharmaceuticals International by 12.8% in the second quarter. Scotia Capital Inc. now owns 43,235 shares of the specialty pharmaceutical company’s stock valued at $747,000 after buying an additional 4,916 shares during the period. Raymond James Financial Services Advisors Inc. increased its position in Valeant Pharmaceuticals International by 85.4% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 76,792 shares of the specialty pharmaceutical company’s stock valued at $1,329,000 after buying an additional 35,378 shares during the period. Chou Associates Management Inc. increased its position in Valeant Pharmaceuticals International by 29.7% in the second quarter. Chou Associates Management Inc. now owns 3,053,843 shares of the specialty pharmaceutical company’s stock valued at $53,030,000 after buying an additional 700,000 shares during the period. Finally, The Manufacturers Life Insurance Company increased its position in Valeant Pharmaceuticals International by 5.0% in the second quarter. The Manufacturers Life Insurance Company now owns 1,059,100 shares of the specialty pharmaceutical company’s stock valued at $18,376,000 after buying an additional 50,529 shares during the period. Institutional investors own 50.49% of the company’s stock.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Analyst Recommendations for Valeant Pharmaceuticals International (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.